Market Overview

Report: Valeant More Likely To Sell Drugs Than Business Units

Share:

Faced with $30 billion in debt, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has few options at its disposal.

Among the company's options to reduce its debt load includes selling off some of its drug assets, or selling complete business units. According to a report by Reuters, Valeant is more likely to sell a "handful" of coveted drugs, including its Xifaxan therapy which is a gastrointestinal antibiotic.

Reuters, citing analysts and investment bankers it interviewed, also added that Valeant could sell its skin care products that fall under its Obagi, Cerave and Solta brand lines.
Also up for sale could be the company's toe fungus treatment, Jublia, that could be worth upwards of $4.5 billion in a potential sale.

The report added that Valeant wants to "stop short" of selling off entire divisions, including Bausch + Lomb, Salix and Medicis. These segments are considered to be "fundamental" to the company's ongoing strategy.

However, analysts aren't fully convinced this is the right path to pursue. Annabel Samimy, an analyst at Stifel, told Reuters that a sale of Bausch + Lomb could net the company as much as $20 billion and "go a long way" toward lowering its debt load.

Shares of Valeant were trading higher by more than 2 percent at $34.13 Tuesday morning.

Posted-In: Annabel Samimy Jublia Obagi salixAnalyst Color Rumors Asset Sales Media

 

Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
PEPMacquarieMaintains138.0
POLBuckinghamMaintains36.0
BKBuckinghamMaintains53.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

iPhone Shipments Down ~44% From Q4 To Q1, According To This Study

The Market In 5 Minutes: Netflix And IBM Get Big Tech Earnings Off On A Rough Start